A detailed history of Mackenzie Financial Corp transactions in Biogen Inc. stock. As of the latest transaction made, Mackenzie Financial Corp holds 14,087 shares of BIIB stock, worth $2.1 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
14,087
Previous 25,664 45.11%
Holding current value
$2.1 Million
Previous $5.95 Million 54.11%
% of portfolio
0.0%
Previous 0.01%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$189.07 - $236.8 $2.19 Million - $2.74 Million
-11,577 Reduced 45.11%
14,087 $2.73 Million
Q2 2024

Aug 14, 2024

SELL
$190.52 - $236.72 $4.11 Million - $5.1 Million
-21,558 Reduced 45.65%
25,664 $5.95 Million
Q1 2024

May 10, 2024

SELL
$212.02 - $267.71 $2.84 Million - $3.59 Million
-13,404 Reduced 22.11%
47,222 $10.2 Million
Q4 2023

Jan 30, 2024

BUY
$222.59 - $267.94 $3.07 Million - $3.7 Million
13,796 Added 29.46%
60,626 $15.7 Million
Q3 2023

Oct 25, 2023

BUY
$253.3 - $285.89 $1.07 Million - $1.2 Million
4,209 Added 9.88%
46,830 $12 Million
Q2 2023

Aug 03, 2023

SELL
$275.25 - $318.06 $816,942 - $944,002
-2,968 Reduced 6.51%
42,621 $12.1 Million
Q1 2023

Apr 24, 2023

SELL
$256.56 - $292.34 $121,609 - $138,569
-474 Reduced 1.03%
45,589 $12.7 Million
Q4 2022

Feb 14, 2023

SELL
$252.44 - $306.72 $1.89 Million - $2.3 Million
-7,491 Reduced 13.99%
46,063 $12.8 Million
Q3 2022

Oct 07, 2022

SELL
$194.69 - $268.46 $2.24 Million - $3.08 Million
-11,486 Reduced 17.66%
53,554 $14.3 Million
Q2 2022

Aug 10, 2022

BUY
$187.54 - $223.02 $3.81 Million - $4.54 Million
20,338 Added 45.5%
65,040 $13.3 Million
Q1 2022

May 13, 2022

BUY
$193.77 - $244.14 $38,172 - $48,095
197 Added 0.44%
44,702 $9.41 Million
Q4 2021

Feb 14, 2022

BUY
$223.92 - $287.77 $1.05 Million - $1.35 Million
4,691 Added 11.78%
44,505 $10.7 Million
Q3 2021

Nov 08, 2021

SELL
$282.99 - $369.05 $1.88 Million - $2.45 Million
-6,627 Reduced 14.27%
39,814 $11.3 Million
Q2 2021

Aug 11, 2021

SELL
$259.0 - $414.71 $292,152 - $467,792
-1,128 Reduced 2.37%
46,441 $16.1 Million
Q1 2021

May 14, 2021

SELL
$242.95 - $284.63 $7.44 Million - $8.72 Million
-30,622 Reduced 39.16%
47,569 $13.3 Million
Q4 2020

Feb 10, 2021

BUY
$236.26 - $355.63 $588,051 - $885,163
2,489 Added 3.29%
78,191 $19.1 Million
Q3 2020

Nov 13, 2020

SELL
$264.77 - $305.71 $1.25 Million - $1.44 Million
-4,716 Reduced 5.86%
75,702 $21.5 Million
Q2 2020

Aug 13, 2020

BUY
$258.66 - $342.55 $15.7 Million - $20.8 Million
60,611 Added 306.01%
80,418 $21.5 Million
Q1 2020

May 14, 2020

SELL
$268.85 - $341.04 $1.7 Million - $2.15 Million
-6,311 Reduced 24.16%
19,807 $6.27 Million
Q4 2019

Feb 13, 2020

SELL
$220.06 - $304.07 $951,539 - $1.31 Million
-4,324 Reduced 14.2%
26,118 $7.75 Million
Q3 2019

Nov 14, 2019

BUY
$217.44 - $243.88 $136,987 - $153,644
630 Added 2.11%
30,442 $7.09 Million
Q2 2019

Aug 14, 2019

SELL
$219.29 - $241.72 $1.74 Million - $1.92 Million
-7,928 Reduced 21.01%
29,812 $6.97 Million
Q1 2019

May 15, 2019

SELL
$216.71 - $338.96 $78.3 Million - $123 Million
-361,413 Reduced 90.54%
37,740 $8.92 Million
Q4 2018

Feb 06, 2019

BUY
$278.5 - $352.75 $19.3 Million - $24.4 Million
69,178 Added 20.96%
399,153 $120 Million
Q3 2018

Nov 15, 2018

BUY
$293.51 - $383.83 $86.6 Million - $113 Million
295,060 Added 845.08%
329,975 $117 Million
Q2 2018

Aug 13, 2018

BUY
$257.52 - $306.91 $214,256 - $255,349
832 Added 2.44%
34,915 $10.1 Million
Q1 2018

May 14, 2018

SELL
$260.13 - $367.91 $7.92 Million - $11.2 Million
-30,461 Reduced 47.19%
34,083 $9.33 Million
Q4 2017

Feb 13, 2018

BUY
$307.64 - $344.58 $19.9 Million - $22.2 Million
64,544
64,544 $20.6 Million

Others Institutions Holding BIIB

About BIOGEN INC.


  • Ticker BIIB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 144,000,992
  • Market Cap $21.5B
  • Description
  • Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...
More about BIIB
Track This Portfolio

Track Mackenzie Financial Corp Portfolio

Follow Mackenzie Financial Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mackenzie Financial Corp, based on Form 13F filings with the SEC.

News

Stay updated on Mackenzie Financial Corp with notifications on news.